FeesSafety
Pluang+

U.S. GoldMining appoints John DeLucchi as director and Audit Committee Chair to boost governance and project growth.

Company Fundamentals
03 Nov 2026, 13:30 WIB
PRNewsWire
View Source
Bullish
U.S. GoldMining appoints John DeLucchi as director and Audit Committee Chair to boost governance and project growth.

U.S. GoldMining Inc. has appointed John DeLucchi as a director and Chair of its Audit Committee, effective November 2, 2026. DeLucchi brings over 35 years of leadership experience, including senior roles at PwC and as CEO of Madison Group, enhancing the company's financial oversight and governance. This move aims to strengthen the development of U.S. GoldMining's Whistler Gold-Copper Project in Alaska, a significant asset with promising growth potential. The company expects DeLucchi's expertise to support strategic growth and stakeholder value creation.

U.S. GoldMining's recent board appointment provides context for readers following gold and basic materials. For readers following basic materials, here is Pluang's market snapshot as of Nov 03, 2026 17:51 WIB: out of 83 priced US stocks, 22 rose and 57 fell. Hecla Mining Company Common Stock (HL) was priced at USD 13.22 with a 1-day change of -2.36%, Franco-Nevada Corporation (FNV) at USD 224.01 with -2.29%, and CRH PLC Ordinary Shares (CRH) at USD 94.40 with -2.27%.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App